354 related articles for article (PubMed ID: 32366856)
1. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Liu S; Qin T; Liu Z; Wang J; Jia Y; Feng Y; Gao Y; Li K
Cell Death Dis; 2020 May; 11(5):309. PubMed ID: 32366856
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib enhanced CD8
Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
[TBL] [Abstract][Full Text] [Related]
4. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
5. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
6. Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.
Gao Y; Feng Y; Liu S; Zhang Y; Wang J; Qin T; Chen P; Li K
Cancer Med; 2023 Jul; 12(14):15337-15349. PubMed ID: 37350549
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
[TBL] [Abstract][Full Text] [Related]
8. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
[TBL] [Abstract][Full Text] [Related]
9. Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma.
Eich ML; Chaux A; Mendoza Rodriguez MA; Guner G; Taheri D; Rodriguez Pena MDC; Sharma R; Allaf ME; Netto GJ
Histopathology; 2020 Feb; 76(3):423-432. PubMed ID: 31494951
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway.
Zhao S; Gao J; Li J; Wang S; Yuan C; Liu Q
Inflammation; 2021 Oct; 44(5):1969-1981. PubMed ID: 34014492
[TBL] [Abstract][Full Text] [Related]
11. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
[TBL] [Abstract][Full Text] [Related]
12. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Spranger S; Spaapen RM; Zha Y; Williams J; Meng Y; Ha TT; Gajewski TF
Sci Transl Med; 2013 Aug; 5(200):200ra116. PubMed ID: 23986400
[TBL] [Abstract][Full Text] [Related]
14. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer cells promote CD169
Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
17. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Sun Z; Nyberg R; Wu Y; Bernard B; Redmond WL
PLoS One; 2021; 16(2):e0247238. PubMed ID: 33596250
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.
Yang Y; Li L; Jiang Z; Wang B; Pan Z
Cancer Immunol Immunother; 2020 Dec; 69(12):2523-2532. PubMed ID: 32577817
[TBL] [Abstract][Full Text] [Related]
19. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
20. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
